Advantage Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Advantage Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$7K	Hold	100	–	–	0.01%	702
2019 Q2	$9K	Hold	100	–	–	0.01%	672
2019 Q1	$9K	Hold	100	–	–	0.01%	661
2018 Q4	$9K	Hold	100	–	–	0.01%	669
2018 Q3	$10K	Hold	100	–	–	0.01%	707
2018 Q2	$9K	Hold	100	–	–	0.01%	660
2018 Q1	$8K	Hold	100	–	–	﹤0.01%	706
2017 Q4	$9K	Hold	100	–	–	﹤0.01%	706
2017 Q3	$9K	Hold	100	–	–	﹤0.01%	708
2017 Q2	$9K	Buy	+100	New	+$9.1K	﹤0.01%	716

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Advantage Investment Management's BMRN Position: Q3 2019 in Review

Advantage Investment Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2019 at 100 shares worth $7K. The position accounts for 0.01% of the portfolio, ranked #702.

Advantage Investment Management first reported a position in BMRN in Q2 2017 and has held it in 10 quarters since. The position peaked at $10K in Q3 2018. 437 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

Advantage Investment Management held 100 shares of BioMarin Pharmaceuticals worth $7K as of Q3 2019.
Advantage Investment Management left its BioMarin Pharmaceuticals share count unchanged in Q3 2019.
BioMarin Pharmaceuticals made up 0.01% of Advantage Investment Management's portfolio in Q3 2019, its #702 holding.
Advantage Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2017 and has held it in 10 quarters since.
Advantage Investment Management's BioMarin Pharmaceuticals position peaked at $10K in Q3 2018.
437 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.